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Metered dose inhalers (MDIs) are the mainstay of inhaled steroid therapy for asthma. With the phasing out of 
traditional chlorofluorocarbon (CFC) propellants and their replacement with a new generation of CFC-free 
products, it is becoming clear that formulation and inhaler characteristics can markedly affect the drug delivery. It 
now seems necessary to compare inhalers not only on the basis of the properties of the steroid molecules but also to 
take into account the effect of propellants and other inhaler characteristics. 
The impact of formulation and delivery device on relative pharmacokinetics, therapeutic efficacy and tolerability 
is illustrated by a new preparation of beclomethasone dipropionate (BDP) in an inhaler containing hydro- 
fluoroalkane (HFA) propellant, called Qvar@ (3M Health Care, U.K.). This drug preparation delivers the majority 
of particles (60%) in the fine particle range. This appears to be associated with improved lung deposition, a halving 
of dose requirements of BDP, but no evidence of clinically relevant adrenal suppression when used in therapeutic 
doses. 
Prescribers need to be aware of the impact of formulation on pharmacokinetics of inhaled steroids in order to offer 
the lowest effective dose and give clear instructions to patients who are changing to a CFC-free product. 
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Introduction 
International and national guidelines agree that inhaled 
steroids should be used regularly as first line therapy for all 
but very mild asthma (l-3). 
Successful management of asthma depends on achieving 
adequate delivery of inhaled drug to the lung with 
minimum systemic glucocorticoid activity. Both the 
drug and the delivery device are therefore important in 
determining the efficacy and safety of inhaled steroids. 
While metered dose inhalers (MDIs) remain the mainstay 
of inhaled steroid therapy, they have traditionally 
contained ozone-depleting chlorofluorocarbon (CFC) 
propellants. However, CFCs are now being phased out in 
agreement with the Montreal Protocol (4), necessitating 
reformulation of MDIs with non-CFC propellants, or a 
change to a different delivery system that does not rely on 
a propellant. 
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It is desirable that these developments in inhaler tech- 
nology also improve delivery of inhaled steroids to the 
areas of lung affected by asthma. Airway inflammation is a 
cardinal feature of asthma. Bronchoscopic studies have 
demonstrated infiltration of the major airways with chronic 
inflammatory cells ($6) and there is now increasing histo- 
pathological evidence for the presence of inflammation in 
the small airways (7-9). These latter pathological changes 
are in keeping with the well-recognized physiological 
changes associated with small airway narrowing in asthma. 
The most widely used inhaled steroids in Europe are 
beclomethasone dipropionate (BDP), budesonide, and 
fluticasone monopropionate. In the past it was possible to 
compare these drugs on the basis of the properties of the 
steroid molecules. Now it is becoming clear that some of the 
new CFC-free formulations themselves can confer different 
properties which markedly affect the efficiency of delivery 
of the inhaled steroid. 
This review addresses the pharmacokinetics, therapeutic 
efficacy and tolerability of BDP, budesonide and fluticasone 
in adults with asthma, with particular reference to Qvar, the 
new preparation of BDP in an inhaler containing 
hydrofluoroalkane (HFA) propellant instead of CFC, 
which has been developed in the U.K. by 3M Health Care. 
Studies in childhood asthma are not included. 
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TABLE 1. Physical and pharmacokinetic properties of inhaled steroids 
Steroid 
Plasma Tissue binding 
Corticosteroid half-life half-life Water solubility 
receptor affinity* 09 (h) Olsml-9 
Beclomethasone dipropionate 0.4 (11) 0.5 (12) - 0.1 (13) 
Beclomethasone monopropionate 13.5 (11) 0.5 (12) 7.5 (14) 10 (13) 
Budesonide 9.4 (11) 2.8 (15) 5.1 (16) 14 (13) 
Fluticasone 18.0 (1l)t 7.8 (17) 10.0 (14) 0.04 (13) 
*Relative to a value of 1 for dexamethasone; tin rat tissue. 
Pharmacology and Pharmacokinetics CFC-CONTAINING MDIs 
Corticosteroid receptors are found in most cell types and 
orally administered steroids therefore have widespread 
effects throughout the body (10). The objective of adminis- 
tering corticosteroids by inhalation is to improve the lung: 
systemic activity ratio compared with oral administration. 
High affinity for the corticosteroid receptor is essential 
for topical activity in the respiratory mucosa. While the 
activities of budesonide and fluticasone are due to the 
parent compounds, that of BDP is largely due to the active 
metabolite 17-beclomethasone monopropionate (17-BMP). 
Any potency comparison between these inhaled steroids 
must therefore take account of the biotransformation 
of BDP to 17-BMP in lung tissue or the gastro-intestinal 
tract (GIT). The affinities of the major inhaled steroids 
for the corticosteroid receptor are fluticasoneb 17-BMP> 
budesonide >BDP (11-17). 
With each actuation, traditional CFC-containing MDIs 
deliver a fixed quantity of drug in suspension. The impor- 
tance of particle size for therapeutic response to inhaled 
drugs has long been recognized; fine particles (those with an 
aerodynamic diameter of less than 5 ,um, often approaching 
1 pm) are more likely to be deposited in the tracheo- 
bronchial and pulmonary regions of the lung, while larger 
particles impact on the oropharynx where they are retained 
or swallowed (23). Studies in asthmatic patients have shown 
the greatest pulmonary response to bronchodilators occurs 
with particles of less than 5 pm diameter, presumably as a 
result of increased airways deposition (24). 
Another important property of inhaled steroids is water 
solubility since this may facilitate dissolution of the steroid 
in the mucosal fluid, the ease of diffusion into and out of 
tissues, and anti-inflammatory potency (18). Lipophilicity is 
the converse of water solubility and this is linked to tissue 
half-life. Budesonide and 17-BMP are more water soluble 
and less lipophilic relative to BDP and fluticasone, and the 
half-life in tissue reflects these findings (Table 1) (11-17). 
Lung deposition studies with bronchodilators show that 
typically only 420% of the delivered dose from a CFC- 
containing MD1 reaches the lung, with around 80% of the 
dose deposited in the oropharynx (25-29). This figure 
assumes good inhaler technique but many patients with 
poor hand-breath coordination use MDIs suboptimally 
(30-32). 
After inhalation, steroids can reach the systemic circula- 
tion via the lung or GIT (Fig. 1) (19,20). Rapid inactivation 
by hepatic biotransformation following systemic absorp- 
tion is desirable to minimize systemic side-effects, and the 
extent of first-pass inactivation in the liver is therefore 
important. All the major inhaled steroids have a high 
first-pass metabolism, with fluticasone being the highest at 
around 99% (15,21,22) (Fig. 1). Metabolic inactivation in 
the lung has not been demonstrated for any of the inhaled 
steroids currently available. 
Despite the availability of these studies with broncho- 
dilators, little has been known about the deposition of 
inhaled steroids from current CFC-containing MDIs until 
recently. Studies have shown that, as with bronchodilators, 
lung deposition seldom represents more than 10% of the 
delivered dose, and oropharyngeal deposition is high 
(29,33-36), presumably as a result of the low proportion of 
particles delivered in the fine particle range (35-38). 
HFA-CONTAINING MDIS 
Delivery Systems 
With the development of a new class of inhalers that utilize 
HFA propellants, it is important to compare their efficacy 
with current products which use either CFC propellants or 
deliver the drug via a dry powder device. 
A number of new CFC-free steroid products are under 
development by different pharmaceutical companies and it 
would appear, at least for the CFC-free BDP MDI, Qvar@, 
that lung deposition is different from that of CFC- 
containing preparations. Laboratory studies have used an 
Andersen Cascade Impactor (Anderson Instruments Inc., 
Smyrna, Georgia) to measure the size distribution of parti- 
cles in an aerosol formulation and the resulting data are 
considered to reflect the likely outcome of human lung 
deposition studies (39). The aerosol is actuated into the 
impactor via an L-shaped tube or throat and passes 
through a series of plates with increasingly smaller pore 
size; those particles with a sufficiently large particle size will 
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FIG. 1. Biotransformation of steroids after inhalation. *, 82% biotransformation to BMP within 5 min (20); 7, more than 
75% conversion to 17-BMP (19). 
impact on the plate, while smaller particles pass on to the 
next stage. Smaller and smaller diameter particles are 
collected at each implication stage. The Anderson Cascade 
Impactor has become a standard tool for assessing particle 
size distribution and is recognized by industry and regulat- 
ory authorities. Andersen Cascade Impactor data demon- 
strate that Qvar@ delivers around 60% of the dose of BDP 
as particles in the fine particle range, mostly at the lower 
size range (mean 1.1 pm) (Fig. 2) (36,40). This compares 
with only 25% of the dose as particles in the fine particle 
range (3.54.0 pm) for CFC-BDP (Fig. 2). As expected, this 
increased proportion of fine particles has translated into 
improved lung deposition, 51% for Qvar compared with 4% 
for CFC-BDP in one study (36). Volunteers acted as their 
own controls and were trained to inhale reproducibly over 
a 3-s inspiration using a real-time breath pattern biofeed- 
back device. Drug and technetium-99 radiolabel validation 
ensured that radiolabelling did not affect the particle size 
distribution. Following inhalation, deposition in lungs, 
abdomen, oropharynx and inhaler adapter, as well as the 
amount the subject expired through a filter trap, were 
determined by gamma scintigraphy. In addition to 
demonstrating increased lung deposition with the HFA- 
formulation, gamma camera imaging showed that BDP 
was deposited throughout the central, intermediate and 
peripheral airways with the HFA formulation whereas 
deposition was predominantly in the central airways with 
the CFC formulation (Fig. 3). An open study in patients 
with mild asthma has confirmed that Qvar@ delivers most 
of the drug (56%) to the lung (36). The smaller particle size 
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FIG. 2. Particle size distribution of BDP in CFC suspen- 
sion (+-) and Qvar (- --) (Andersen Cascade Impactor 
Components). 
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FIG. 3. Lung deposition of BDP after inhalation of CFC suspension and Qvar@ (36). Reprinted with permission from 
W.B. Saunders Respiratory Medicine 1998; 92 (Suppl. A). Leach C, Improved delivery of inhaled steroids to the large and 
small airways. 
and improved lung deposition have been brought about by 
modifying the inhaler characteristics and replacing the 
conventional suspension of BDP in two CFC propellants 
and a surfactant, with a solution of BDP in HFA-134a. 
HFA-134a is an alternative non-CFC propellant, the safety 
of which has been extensively evaluated (41,42). This 
improved pattern of drug distribution is seen with or 
without the use of a spacer (AeroChamber@, Trude II, 
Ontario), as confirmed by a deposition study in healthy 
subjects using the methodology described above (43). 
This altered deposition has implications for the 
pharmacokinetics of BDP. The pharmacokinetics of both 
single and multiple doses of Qvar have been compared with 
CFC-BDP (19). Both studies showed that half the dose of 
the HFA-based formulation gave similar serum drug con- 
centration (using a novel beclomethasone assay procedure) 
to CFC-BDP. The maximum serum drug concentration and 
the area under the time concentration curve values for half 
the dose of the HFA formulation were similar to those with 
CFC-BDP. 
With HFA-containing inhalers, deposition may be influ- 
enced by the physical interaction between the propellant 
and the particular drug. Thus particle size and deposition of 
salbutamol HFA-MD1 is similar to that from a conven- 
tional CFC-containing MD1 (35). The small particle size of 
Qvar@ is in part due to the solution of BDP in HFA-134a 
but in addition the design of the inhaler valve and adapter, 
as well as the additive mixture used, will all influence 
particle size. It cannot therefore be assumed that the same 
particle size profile will apply to other CFC-free steroid 
MDIs currently under development by a number of 
pharmaceutical companies. Indeed, two recent product 
introductions [CFC-free BDP (Beclazone, Norton, 
Eire); CFC-free fluticasone (Flixotide, Glaxo-Wellcome, 
Germany)] have published dosing characteristics similar to 
the CFC-containing inhalers that they replace (44,45). 
SPACERS AND BREATH-ACTUATED AEROSOLS 
In patients with poor coordination, spacer devices used in 
combination with an MD1 can help to improve the amount 
of drug received. Spacers form a reservoir from which 
patients can inhale the aerosol, allowing rapidly moving 
particles to slow down and larger particles to evaporate and 
reduce in size, thereby decreasing oropharyngeal deposition 
(46). However, delay between actuation and inhalation 
and the practice of multiple actuation before inhalation 
can have a major impact on the delivered dose (47,48). 
Furthermore, these devices can be bulky and cumbersome 
to use. 
Breath-actuated aerosols offer an alternative approach to 
overcoming the problem of poor coordination because the 
release of a metered dose of drug is triggered by inspiration. 
Lung deposition studies using a breath-actuated Qvar@ 
inhaler (Autohale@, 3M Health Care, U.K.) have been 
performed in asthmatic patients (49). The device operated 
consistently over a wide range of inspiratory flows (26 
137 1 min- ‘) and actuated very early in the inspiratory 
cycle (0.2 s) (SO), with delivery to the lungs of 56% of 
ex-actuator dose (49). 
DRY POWDER INHALERS (DPIs) 
DPIs offer a CFC-free preparation of inhaled steroids that 
overcomes the problem of poor hand-mouth coordination. 
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The drug is held as dry powder, either in a capsule which is 
perforated manually just before inhalation, or in a reservoir 
from which a dose is released manually just before inhala- 
tion. These devices are thus breath-dependent rather than 
breath-actuated devices and the medication delivery and 
fine particle mass of DPIs are dependent on the individual 
device and inspiratory flow rate of the patient, with optimal 
delivery of drug occurring at flow rates of 60 1 min ~ ’ 
(3851). 
Studies using a budesonide DPI (Pulmicort Turbu- 
baler;“?, Astra, Sweden) in healthy volunteers have sug- 
gested that lung deposition is approximately twice as great 
and dose consistency is less variable with DPIs than with 
budesonide CFC-MDIs (33,52), although this conclusion is 
not universally accepted and other studies have shown dose 
consistency to be more variable with DPIs (3853). 
NEBULIZERS 
With nebulizers, even slow vital capacity inhalations have 
given good pulmonary deposition patterns (54) and hand- 
breath coordination is not required. However, there is no 
evidence that nebulizers are superior to hand-held inhalers 
or oral steroids (55) and their use is generally reserved for 
young or elderly patients who cannot cope with other 
devices (46). At the present time, budesonide is the only 
steroid available for administration by nebulizer. 
Comparative Efficacy 
National and international guidelines recommend a step- 
wise approach to the management of asthma (l-3). 
Standard-dose inhaled steroid therapy is generally regarded 
aS 1004OO~g twice daily for BDP or budesonide and 
50-2OOpg twice daily for fluticasone. High-dose therapy is 
regarded as 800-2000,~g daily for budesonide or BDP and 
400-1OOOpg daily for fluticasone (3). The efficacy of 
standard-dose inhaled steroids was well documented as 
early as the 1970s. High-dose inhaled steroids offer clear 
benefits to certain patient groups although this has been 
more difficult to demonstrate, due in part to methodologi- 
cal difficulties in determining a dose-response relationship 
to inhaled steroids (56). 
Clinical trials comparing the efficacy of BDP and 
budesonide in standard or high doses for the treatment of 
asthma generally show no clinically relevant differences 
between the two drugs. Over 20 such studies have been 
reviewed elsewhere (5658). More recent comparisons 
(59-62) have employed different delivery devices, making it 
difficult to draw conclusions about the relative efficacy of 
the two steroid molecules. In these studies, there was some 
evidence that equal doses of BDP delivered by CFC- 
containing MD1 were less effective than budesonide 
delivered by dry powder reservoir, arguing in favour of 
using budesonide delivered by a dry powder device. How- 
ever, against this, a comparison of multiple dose-levels of 
BDP with multiple dose-levels of budesonide failed to show 
a dose-response for either drug, or any significant difference 
between drugs (63). 
Studies comparing fluticasone with either BDP or 
budesonide in standard or high doses delivered by CFC- 
containing MDIs and dry powder devices have also been 
reviewed elsewhere (6466). The majority of studies have 
compared a single dose-level of fluticasone with twice the 
dose of BDP or budesonide and have shown no differences 
between treatments when given by equivalent delivery sys- 
tems, supporting the view that fluticasone is twice as 
effective as BDP or budesonide (67-72). In a meta-analysis 
of clinical studies comparing fluticasone and budesonide, 
fluticasone at half the budesonide dose resulted in a slightly 
greater improvement in morning peak expiratory flow and 
had less of an effect on cortisol(73). The efficacy ratio of 2:l 
of fluticasone over BDP or budesonide has been more 
difficult to demonstrate in studies attempting to show a 
dose response to inhaled steroids (74,75). 
Preliminary studies with Qvar@ were carried out in small 
numbers of patients to establish its clinical efficacy at doses 
recommended for CFC-BDP (76). In a study by Dahl et al., 
68 patients with asthma who were well controlled on 
CFC-BDP 200-600 pg day ~ ’ were included in a double- 
blind, two-period cross-over study (76). Patients were 
randomized to receive the same total daily dose of CFC- 
BDP or Qvar for 4 weeks. Measurements of asthma control 
[morning and evening peak expiratory flow, forced expira- 
tory volume in 1 s (FEV,), asthma symptom score, sleep 
disturbance or P-agonist use] showed statistically significant 
equivalence between CFC-free and CFC-based BDP 
(P<O.OOl). However, the patient population in this study 
was comparatively small and the study was not designed to 
establish equivalence. Therefore, having established that 
the new BDP formulation could benefit patients with 
asthma, subsequent parallel-group studies were carried out 
to establish the optimal dose of Qvar and to evaluate its 
efficacy and safety in a wide range of degrees of asthma 
severity and in different patient types. 
In a dose-response comparison of CFC-BDP and Qvar@, 
a statistically significant dose-response relationship was 
demonstrated for both products over the range 100~8OOpg 
(Qvar P=O.O09, CFC-BDP P=O.O03, for linear trend; Fig. 
4) (78-81). Three hundred and twenty-three patients with 
moderately severe asthma were on a stable regimen of 
400-1OOOpg daily of inhaled corticosteroid with use of an 
inhaled P-agonist on an as-needed basis, and had a FEV, of 
50-75% predicted. Lung function parameters [FEV,, forced 
expiratory flow at mid-expiratory phase (FEF2,- ,J, morn- 
ing peak expiratory flow (PEF) and per cent reversibility] 
were measured during a 7-14 day run-in period (inhaled 
steroid continued), during a l-28 day single-blind inhaled 
steroid wash-out period (placebo inhaler used), and during 
6 weeks of double-dummy, modified blind, randomized 
treatment (Qvar or CFC-BDP at 100,400 or 8OOpg daily). 
In addition to confirming a dose-response relationship for 
BDP, this study also showed that higher doses of CFC- 
BDP than of Qvar were required to achieve the same 
improvement in FEV, [relative dose ratio of 2.6 (95% CI 
1. l-l 1.6) Finney’s Parallel Line Bioassay method] and 
FEFs,z [relative dose ratio of 3.2 (95% CI 1.3-15.8) 
Finney’s Parallel Line Bioassay method]. The novel design 
of this study overcomes many of the limitations of earlier 
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FIG. 4. (a) Change from baseline at week 6 in FEV, as % 
of predicted value: CFC-BDP ( -) suspension vs. 
Qvar@ (---) (78-81) (0, lOOpug; 0, 4OOpg; A, SOOpg). 
b) At week 6 there was a statistically significant linear 
trend for increased improvement with increasing doses of 
both Qvar@ (- - -) and CFC-BDP ( -) [relative dose 
ratio 2.6 (95% CI 1.1-11.6)]. 
dose-response studies. Notably, steroid responsiveness was 
demonstrated following withdrawal of inhaled steroids in 
the run-in period, and patients were required to visit the 
clinic five times per week during the run-in, wash-out, and 
randomized treatment periods, to ensure proper MDI, PEF 
and spirometry technique. 
Other studies support the finding of lower effective doses 
of Qvar@ compared with CFC-BDP (82-84). In 347 
patients with moderate to severe asthma, 400,~g Qvar was 
equivalent to 800,~g CFC-BDP (83), while in 233 patients 
with moderately severe asthma who were inadequately 
controlled on current inhalation therapy, 8OOpg was 
equivalent to 15OOpg CFC-BDP (82). Both these studies 
employed double-blind, parallel group designs with 12 
weeks on randomized therapy, and efficacy variables 
included morning and evening PEF, FEV,, asthma symp- 
toms and P-agonist use. In steroid-naive patients with mild 
to moderate symptomatic asthma, daily doses as low as 
100 pg or 200 ,ug Qvar were significantly more effective than 
placebo in improving asthma control (85). 
Tolerability and Adverse Effects 
It should be stressed that, in general, inhaled steroids are 
remarkably safe. Of the few recognized side-effects, there is 
a low incidence of oral candidiasis. There is also the 
problem of hoarseness, probably related to laryngeal 
deposition and an associated steroid myopathy. One of the 
potential advantages of the HFA-BDP aerosol from 3M 
Health Care (Qvar) is that, because of the predominance of 
small particles, the majority of drug is delivered to the 
airways with reduced deposition in the throat. Early indi- 
cations suggest that the incidence of local side-effects is low; 
in five multicentre clinical trials involving 740 patients on 
Qvar, throat swabs taken from patients reporting any 
oropharyngeal adverse event did not reveal any evidence of 
candidiasis. The incidence of dysphonia was comparable in 
both the Qvar@ and CFC-BDP groups (3%) (86). 
Oral corticosteroid therapy may give rise to systemic 
adverse effects associated with significant suppression of 
adrenal function. Bone loss and osteoporosis, skin thinning, 
and increased cataract formation have all been reported 
and decreased linear growth may be an issue in children. 
There is concern that these effects may also be seen with 
inhaled steroids, particularly when high doses are used long 
term. 
EFFECTS ON HYPOTHALAMIC-PITUITARY- 
ADRENAL (HPA) FUNCTION 
Extensive clinical use of inhaled BDP and budesonide at 
doses less than IOOO~g daily, over the past l-20 years, 
suggests that in adults, inhaled therapy with these agents is 
not associated with clinically relevant adrenal suppression. 
There has been much discussion over the preferred methods 
of evaluating the effect on hypothalamic-pituitary axis 
(HPA) function following the use of inhaled steroids. The 
different sensitivities of the variety of methods used do, to 
some extent, confound the interpretation of findings across 
the different inhaled steroids, as do the different inhaler 
devices used (18). 
In general, dose-related suppression of the HPA axis has 
occurred with inhaled BDP or budesonide doses in excess of 
1OOOpg daily (66). For budesonide and fluticasone, which 
undergo 89 and 99% first pass hepatic metabolism respect- 
ively, lung bioavailability is the main determinant of sys- 
temic activity. For BDP, which has lower hepatic first pass 
extraction (79%) (19), gut bioavailability assumes greater 
importance (66). Thus, use of a spacer has been shown to 
decrease adrenal suppression caused by BDP (87). 
The relatively low incidence of adrenal suppression with 
Qvar@ in clinical studies is reassuring since it confounds the 
expectation that greater lung deposition (which results in 
more drug absorption from the lung) may adversely affect 
adrenal function. Morning plasma cortisol concentrations, 
INHALED STEROIDS 155 
TABLE 2. Traditional corticosteroid inhalers available in the U.K. 
Steroid Device Brand (manufacturer) Strength @g) Propellant 
Beclomethasone MD1 Beclazone (BN) 50, 100, 250 CFC 
dipropionate Becloforte (GW) 250 CFC 
Becotide (GW) 50, 100, 200 CFC 
Filair (3M) 50, 100, 250 CFC 
MD1 + integral Becloforte Integra (GW) 250 CFC 
compact spacer Asmabec Spacehaler (Evans) 50, 100, 250 CFC 
BA MD1 AeroBec Autohaler (3M) 50, 100, 250 CFC 
BA MD1 +integral Becloforte Easi-Breathe (GW) 250 CFC 
compact spacer Becotide Easi-Breathe (GW) 50, 100 CFC 
Single-dose DPI Becotide Rotacaps and Rotahaler (GW) 100, 200, 400 None 
Multiple-dose DPI Becloforte Disks and Diskhaler (GW) 400 None 
Becodisks and Diskhaler (GW) 100, 200, 400 None 
Budesonide MD1 Pulmicort (AP) 50, 200 CFC 
Reservoir DPI Pulmicort Turbuhaler (AP) 100, 200, 400 None 
Fluticasone propionate MD1 Flixotide (GW) 25, 50, 125, 250 CFC 
Reservoir DPI Flixotide Accuhaler (GW) 50, 100, 250, 500 None 
Multiple-dose DPI Flixotide Disks and Diskhaler (GW) 50. 100, 250, 500 None 
MDI, metered dose inhaler; BN, Baker Norton; GW, Glaxo Wellcome; 3M, 3M Health Care; CFC, chlorofluorocarbon; BA, 
breath actuated; DPI, dry powder inhaler; AP, Astra Pharmaceuticals. 
measured after 12 weeks of randomized treatment in two 
studies conducted for licensing purposes, support this asser- 
tion. In the first study (n=347) (83), cortisol levels were 
normal in over 96% of patients in each of three treatment 
groups (Qvar 4OOpg daily, HFA placebo, CFC-BDP 
8OOpg daily). In the second study (n=233) (82), a direct 
comparison of Qvar 8OOpg daily with CFC-BDP 1500,~~g 
daily, significantly fewer Qvar patients than CFC-BDP 
patients had below normal morning plasma cortisol values 
(4.4% vs. 14.6%; PzO.024, Fisher’s exact test). In this study 
the two treatments were also comparable on all efficacy 
variables. 
EFFECTS ON BONE TURNOVER 
It cannot be assumed that systemic effects in various areas, 
e.g. adrenal function and bone turnover, will occur concur- 
rently and to the same degree. For this reason, the effects on 
all relevant organ systems influenced by corticosteroids 
need be assessed separately. Measurement of markers of 
bone formation must be accompanied by measurement of 
markers of bone resorption, as the two processes are linked 
in the dynamic process of bone turnover, 
In general, it is accepted that inhaled BDP and budeso- 
nide in dosages up to 800,~g daily are relatively free of 
effects on bone metabolism (66). However, this is based on 
a combination of short-term studies of biochemical markers 
of bone turnover and uncontrolled observations from clini- 
cal use over many years. There are currently insufficient 
data on HFA-BDP to make any worthwhile comparisons 
with other inhaled steroids. Two studies comparing flutica- 
sone with budesonide have found the effects of the two 
drugs on markers of bone metabolism to be similar (75,88). 
There is considerable debate as to the clinical significance 
of short-term studies using biochemical markers. In some 
studies, reductions in serum osteocalcin (a marker of bone 
formation) were paralleled by reductions in bone density 
(89), while in others no correlation between the two 
measurements could be found (90). A review of nine 
published surveys of bone mineral density in patients 
receiving inhaled steroids has shown conflicting results 
(91). 
It is often difficult to separate out the effects of high-dose 
inhaled steroids from the effects of previous oral corticos- 
teroid exposure. A cross-sectional survey found that bone 
mineral density increased with increased cumulative inhaled 
steroids dose and vertebral fracture rate decreased with 
increased cumulative inhaled steroids dose (92). This may 
reflect bone repair following withdrawal from oral steroids. 
Prospective long-term monitoring of bone density and 
fracture incidence, in patients receiving long-term inhaled 
corticosteroids, may prove the only way to determine 
clinical risk. 
OTHER SERIOUS ADVERSE EFFECTS 
Increased cataract formation and diabetes mellitus may 
complicate treatment with oral corticosteroids but do not 
appear to be a problem with inhaled steroids, even in high 
doses (93). 
Skin thinning and purpura have been associated with use 
of high-dose inhaled steroids (94). Easy bruising has been 
reported in patients on high-dose inhaled steroids, and the 
risk increased with age, dose and duration of use (95). 
Neutrophilic leucocytosis, eosinopenia and lymphopenia 
have been reported with high-dose inhaled steroids but to a 
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TABLE 3. HFA-corticosteroid inhalers recently introduced in Europe 
Steroid Device Brand (manufacturer) Strength @g) Country 
Beclomethasone dipropionate MD1 Beclazone CFC-free (BN) 50, 100, 250 Eire 
Qvar@ (3M) 50, 100 U.K. 
BA MD1 Qvar Autohaler (3M) 50, 100 U.K. 
Fluticasone MD1 Flixotide Evohaler (GW) 125, 250 Germany 
MDI, metered dose inhaler; BN, Baker Norton; 3M, 3M Health Care; BA, breath actuated; GW, 
Glaxo Wellcome. 
TABLE 4. Requirements for optimal inhaler use* 
Requirement 
MD1 DPI 
CFC Qvar@ 
Press & Breath Press & Breath Capsules/ 
breathe actuated breathe actuated disks Reservoir 
Manual dexterity P I( I( I( d I( 
Hand-breath coordination (/ P (/ I( I( % 
High inspiratory flow rate P I( % % d d 
Shake before use d r/ I( I( I( % 
Prime after first use bJ d I( % I( I( 
(/, Mandatory; I(, not required. 
*Sources: Manufacturers’ Patient Information Leaflets, MIMS Guides to asthma devices (103), and 
Ariyananda et al. (46). 
TABLE 5. Transferring patients to Qvar @ from a CFC-BDP or other steroid inhaler 
Daily dose of beclomethasone dipropionate @g) 
CFC-BDP inahler , 200-250 400-500 800-1000 1200-1500 1600-2000 
Budesonide 200-250 400-500 800-1000 1200-l 500 1600-2000 
Fluticasone 100 200 400 600 800 
Qvar 100 200 400 600 800 
lesser extent than with oral therapy. They have not been 
associated with clinically significant adverse effects (96,97). 
Effects of inhaled steroids on growth in children is a 
subject that has received much attention (98-100) but this is 
outside the remit of this paper, which is concerned only 
with asthma in adults. 
Practical Aspects of Therapy 
The implications of the introduction of a range of CFC-free 
inhaled steroids are not trivial. There are a number of 
different inhaled steroid products available in the U.K. 
(Table 2) and CFC-free steroids MDIs in Europe (Table 3). 
The important differences in the pharmacokinetics of these 
drugs will need to be considered when treating patients and 
addressing the traditional problems of offering the lowest 
effective dose, maximizing compliance (101,102) and over- 
coming poor inhaler technique (Table 4) (30,32,46,103). It 
is going to be vital that prescribers understand that one 
CFC-free steroid inhaler (Qvar@) can be used at half the 
traditional dose of CFC-BDP (44,45) or budesonide 
inhalers, and at the same total daily dose of fluticasone 
preparations (Table 5). We look to future editions of the 
British Thoracic Society guidelines to help clinicians take 
best advantage of the new range of CFC-free inhaled 
steroids. 
Conclusions 
Some patients may require high doses of inhaled steroid to 
control their asthma and individual titration is essential; the 
lowest maintenance dose that is consistent with efficacy 
should be used to avoid dose-related effects on adrenal 
function and bone metabolism. 
There is considerable variation between inhaler devices as 
to the amount of drug deposited in the lung and therefore 
contributing to therapeutic effect, and the amount 
deposited in the oropharynx and therefore contributing to 
unwanted systemic and local effects. These differences will 
be compounded as new products reach the market and it 
cannot be assumed that equal doses of the same drug from 
different inhalation devices will be bioequivalent. 
While some CFC-free inhalers are likely to be therapeu- 
tically equivalent to the CFC-containing products they 
replace, others are not. There are now considerable data to 
indicate that the 3M Qvar@ has reduced dose requirements 
of BDP by approximately half compared with traditional 
CFC-MDIs while increasing deposition in the smaller air- 
ways. In the light of this, the U.K. Department of Health 
has recommended that Qvar should be prescribed only by 
brand name (104). 
It is vital that prescribers and the entire health-care team 
are aware of these differences and give clear guidance to 
patients who are changing from a CFC-BDP MD1 to Qvar, 
since stepping down the dose of inhaled steroid should be 
possible. 
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